MEDICAL CHEMICAL DEFENSE (EMD)

Abstract

This project provides for the development of medical materiel and other medical equipment items necessary to provide an effective capability for medical defense against chemical warfare agent threats facing U.S. forces in the field. This project supports efforts in the System Development and Demonstration (SDD) phase of the acquisition strategy for prophylactic, pre-treatment, and therapeutic drugs and diagnostic medical devices for the protection, treatment, detection, and medical management of chemical warfare agent exposures. Project funds research and development of safety studies, manufacturing scale-up, process validation, drug interaction, performance test, and submission of the Food and Drug Administration (FDA) drug licensure application(s). This program currently funds: (1) Bioscavenger (BSCAV), a new capability, to be used as a prophylaxis against nerve agents; (2) Advanced Anticonvulsant System (AAS), which consists of the drug midazolam in an autoinjector, to be used as an enhanced treatment for nerve agent induced seizures and will be a replacement for the currently fielded Convulsant Antidote for Nerve Agent (CANA) autoinjector, which uses diazepam; and (3) Improved Nerve Agent Treatment System (INATS) an enhanced nerve agent treatment regimen consisting of an improved oxime to replace the current fielded oxime 2-pralidoxime chloride (2-PAM), a centrally acting therapeutic to increase survival, and studies to generate data to support use of pyridostigmine bromide (PB), as a pretreatment for nerve agents in addition to soman.

Open PDF

Document Details

Document Type
Project
Publication Date
Oct 01, 2016
Source ID
MC5_0604384BP_5_0400_PB_2016

Tags

Fields of Study

  • Medicine

Readers

  • Critical Infrastructure Protection in CBRN and WMD Threats.
  • Neurotoxicology

Related Documents